Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462077 | 1.00 | PREP (0.47) | PREPAAK1HDAC1HDAC2CHRM2 | |
| SCHEMBL16541368 | 1.00 | PREP (0.47) | PREPAAK1HDAC1HDAC2CHRM2 | |
| SCHEMBL203803 | 0.92 | AAK1 (0.52) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL2707662 | 0.92 | AAK1 (0.52) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL16004387 | 0.92 | AAK1 (0.52) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL18993181 | 0.92 | AAK1 (0.52) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL14948527 | 0.87 | PREP (0.46) | PREPAAK1CHRM2CHRM1CHRM3 | |
| SCHEMBL15406118 | 0.85 | PREP (0.42) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL15406119 | 0.85 | PREP (0.42) | PREPAAK1HDAC1CHRM2CHRM1 | |
| SCHEMBL18849730 | 0.80 | PREP (0.42) | PREPCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855478-B1 | LEDIPASVIR D-TARTRATE | GILEAD PHARMASSET LLC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170327488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9682987-B2 | Solid forms of an antiviral compound | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327488-A1 | SOLID FORMS OF AN ANTIVIRAL COMPOUND | EIF2AK2, ZC3HAV1, ZC3HAV1L | PREP 2628/4885AAK1 1608/4885HDAC1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.